Cidara Therapeutics (NASDAQ: CDTX) saw its stock rise nearly 7% on Friday, significantly outperforming the S&P 500’s 0.6% increase, following the announcement that the first patients had been dosed in a phase 3 trial for its investigational flu treatment, CD388. This positive development came just after market close on Thursday, boosting investor confidence in the biotech firm.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
